1. How many CCS- and ACS-patients might reach the newly recommended LDL-C-target <55mg/dl in clinical practice if guidelines were applied – an estimate from the DYSIS II study population. (25th November 2020) Authors: Gitt, A.K; Horack, M; Lautsch, D; Zahn, R; Ferrieres, J Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P5383Risk for major adverse cardiovascular events estimated by the TIMI Risk Score for Secondary Prevention TRS2P in patients with coronary artery disease did not impact lipid lowering treatment in clinica. (28th August 2018) Authors: Gitt, A K; Lautsch, D; Lautsch, D; Horack, M; Horack, M; Baxter, C A; Baxter, C A; De Ferrari, G; De Ferrari, G; Ferrieres, J; Ferrieres, J Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P781Better LDL-cholesterol-target attainment in patients with ACS and type 2 diabetes - results of DYSIS II ACS. (28th August 2018) Authors: Gitt, A K; Lautsch, D; Horack, M; Baxter, C A; Ferrieres, J; De Ferrari, G Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗